Kidney disease mechanisms associated with human genetic variation
与人类遗传变异相关的肾脏疾病机制
基本信息
- 批准号:9284462
- 负责人:
- 金额:$ 22.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-20 至 2017-08-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS-Associated NephropathyAPOL1 geneAddressAfricanAfrican AmericanAmericanAnimalsApolipoproteinsAutophagocytosisAutophagosomeBindingBiologicalBiologyBiopsy SpecimenBloodCardiovascular DiseasesCell Culture TechniquesCell LineCellsCessation of lifeChromosomes, Human, Pair 22Chronic Kidney FailureCodeComplementary DNAComplexDataDevelopmentDiagnosisDiseaseDockingElectron MicroscopyEnd stage renal failureEnvironmental Risk FactorExpenditureExperimental DesignsFRAP1 geneGene Expression ProfileGenetic EpistasisGenetic Predisposition to DiseaseGenetic VariationGenotypeGoalsHIVHIV InfectionsHIV-1HaplotypesHealthcareHome environmentHomeostasisHumanHuman GeneticsImmunofluorescence ImmunologicIn SituIn Situ HybridizationIn VitroInfectionInfection preventionInjuryKidneyKidney DiseasesKidney FailureKnowledgeLocationLysosomesMapsMediatingMedicareMetabolicMethodsModelingMusNPHS2 proteinNormal tissue morphologyPathogenesisPathologyPathway interactionsPatientsPatternPhenotypePreventionProtein BiosynthesisProteinsPublishingRegulationResistanceRiskSNAP receptorSeveritiesSignal TransductionStressStudy modelsSusceptibility GeneTestingTimeTissuesTransgenic MiceTrypanosomaUnited StatesVariantViralViral ProteinsVirusbasediabeticdisease diagnosisdisease phenotypeexperimental studygenetic associationhealth disparityhigh risk populationimprovedin vivoin vivo Modelmouse modelnef Proteinnephrinnon-diabeticnoveloverexpressionparticlepathogenpodocytepromoterpublic health relevanceresponserisk varianttransgene expressionuptakevector
项目摘要
DESCRIPTION (provided by applicant): Chronic kidney disease (CKD), like many complex disease phenotypes, reflects dependent interactions between genetic susceptibilities and environmental factors. APOL1 variants explain much of the excess risk of advanced non-diabetic CKD in patients of African ancestry. However, only some patients with risk genotypes develop kidney disease, suggesting that genetic epistasis or environmental stress is required to trigger variant APOL1-dependent kidney injury. To investigate how APOL1 variants result in CKD, we have focused on HIV- associated nephropathy (HIVAN), the disease most robustly associated with APOL1 risk haplotypes and clearly dependent on an environmental factor, HIV-1 infection. Our preliminary data demonstrate APOL1 is expressed in the podocyte, and APOL1 overexpression activates autophagy. Although mTor-dependent suppression of core autophagy may cause diabetic glomerulopathy, a renal pathology not associated with APOL1 variants, we provide evidence that the genetic association of APOL1 with CKD results from APOL1- dependent regulation of distinct, selective autophagy pathways, which result in the destruction of pathogens. We hypothesize that APOL1 is an autophagic adaptor that tethers a docking SNARE (VAMP8) displayed on lysosomes to the autophagosomal protein LC3-II. The tethering function of APOL1 is activated by binding a triggering molecule, the HIV protein Nef, and results in the selective degradation of autophagosomes carrying HIV viral particles and proteins. Variant APOL1 proteins are functionally defective, permitting HIV to persist in the infected cell and continue synthesis of viral proteins including Nef. Nef blocks autophagic elimination of the virus and is critical for development of HIVAN. Our proposed experiments address three unanswered and novel questions regarding APOL1 function in CKD. Is APOL1 synthesized in situ in kidney and what is its subcellular home? Does circulating or renal-expressed variant APOL1 mediate kidney disease? Does dysregulation of autophagy pathways activated in response to specific environmental stresses result in kidney disease in patients with APOL1 risk genotypes? These questions are addressed with the following Specific Aims: 1. Determine APOL1 expression and intracellular location in normal kidney, and determine if APOL1 localization varies with risk genotype and/or disease diagnosis; 2. Generate in vivo models for the study of APOL1 function; 3. Characterize protein interactions between APOL1 with VAMP8 and the HIV protein Nef and examine normal and variant APOL1 regulation of autophagy in cell lines and cultured podocytes. These studies can result in novel, mechanism-based therapies, improve health disparities in African American patients and identify novel mechanisms of human CKD.
描述(由申请人提供):慢性肾脏疾病(CKD),像许多复杂的疾病表型一样,反映了遗传易感性和环境因素之间的依赖相互作用。APOL1变异解释了非洲血统患者晚期非糖尿病性CKD的过度风险。然而,只有一些具有风险基因型的患者会发生肾脏疾病,这表明遗传上位或环境应激是触发变异型apol1依赖性肾损伤的必要条件。为了研究APOL1变异如何导致CKD,我们将重点放在HIV相关肾病(HIVAN)上,这种疾病与APOL1风险单倍型最密切相关,并且明显依赖于环境因素HIV-1感染。我们的初步数据表明,APOL1在足细胞中表达,并且APOL1过表达激活自噬。尽管mtor依赖的核心自噬抑制可能导致糖尿病肾小球病变,这是一种与APOL1变异无关的肾脏病理,但我们提供的证据表明,APOL1与CKD的遗传关联源于APOL1依赖的不同的、选择性的自噬途径的调节,这导致病原体的破坏。我们假设APOL1是一种自噬接头,将显示在溶酶体上的对接SNARE (VAMP8)连接到自噬体蛋白LC3-II上。APOL1的栓系功能通过结合触发分子HIV蛋白Nef而激活,并导致携带HIV病毒颗粒和蛋白质的自噬体选择性降解。变异APOL1蛋白在功能上存在缺陷,允许HIV在感染细胞中持续存在,并继续合成包括Nef在内的病毒蛋白。Nef阻断病毒的自噬消除,对hiv的发展至关重要。我们提出的实验解决了关于APOL1在CKD中的功能的三个未解之谜和新问题。APOL1是在肾脏原位合成的吗?它的亚细胞家园是什么?循环或肾脏表达的APOL1变体介导肾脏疾病吗?在APOL1风险基因型患者中,响应特定环境应激激活的自噬通路失调会导致肾脏疾病吗?这些问题的具体目的如下:测定正常肾脏中APOL1的表达和细胞内定位,并确定APOL1定位是否随风险基因型和/或疾病诊断而变化;2. 建立体内模型,研究APOL1的功能;3. 表征APOL1与VAMP8和HIV蛋白Nef之间的蛋白相互作用,并检查正常和变异APOL1对细胞系和培养足细胞自噬的调节。这些研究可以产生新的、基于机制的治疗方法,改善非裔美国患者的健康差异,并确定人类慢性肾病的新机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Leslie A Bruggeman其他文献
Leslie A Bruggeman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Leslie A Bruggeman', 18)}}的其他基金
Mechanisms of Kidney Diseases Associated With APOL1 Variation
APOL1 变异相关肾脏疾病的机制
- 批准号:
10607630 - 财政年份:2023
- 资助金额:
$ 22.21万 - 项目类别:
Intracellular functions of APOL1 in the kidney
APOL1 在肾脏中的细胞内功能
- 批准号:
10383979 - 财政年份:2021
- 资助金额:
$ 22.21万 - 项目类别:
Intracellular functions of APOL1 in the kidney
APOL1 在肾脏中的细胞内功能
- 批准号:
10493392 - 财政年份:2021
- 资助金额:
$ 22.21万 - 项目类别:
Intracellular functions of APOL1 in the kidney
APOL1 在肾脏中的细胞内功能
- 批准号:
10666584 - 财政年份:2021
- 资助金额:
$ 22.21万 - 项目类别:
Intracellular functions of APOL1 in the kidney
APOL1 在肾脏中的细胞内功能
- 批准号:
10252083 - 财政年份:2020
- 资助金额:
$ 22.21万 - 项目类别:
Kidney disease mechanisms associated with human genetic variation
与人类遗传变异相关的肾脏疾病机制
- 批准号:
8642932 - 财政年份:2014
- 资助金额:
$ 22.21万 - 项目类别:
Kidney disease mechanisms associated with human genetic variation
与人类遗传变异相关的肾脏疾病机制
- 批准号:
9653298 - 财政年份:2014
- 资助金额:
$ 22.21万 - 项目类别:
Cell junction proteins in podocyte injury repair
足细胞损伤修复中的细胞连接蛋白
- 批准号:
8342329 - 财政年份:2012
- 资助金额:
$ 22.21万 - 项目类别:














{{item.name}}会员




